Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21328019 | 0.92 | ALDH1A1 (0.39) | ALDH1A1CYP3A4CYP2C19CYP2C9POLB | |
| SCHEMBL14127677 | 0.85 | POLB (0.38) | ALDH1A1CYP3A4CYP2C19CYP2C9POLB | |
| SCHEMBL1812258 | 0.85 | ALDH1A1 (0.43) | ALDH1A1CYP3A4CYP2C19CYP2C9POLB | |
| SCHEMBL2289941 | 0.84 | — | — | |
| SCHEMBL24580648 | 0.84 | ALDH1A1 (0.42) | ALDH1A1CYP3A4CYP2C19CYP2C9POLB | |
| SCHEMBL19555323 | 0.82 | ALDH1A1 (0.41) | ALDH1A1CYP3A4CYP2C19CYP2C9POLB | |
| SCHEMBL22955528 | 0.82 | ALDH1A1 (0.41) | ALDH1A1CYP3A4CYP2C19CYP2C9POLB | |
| SCHEMBL14212551 | 0.82 | ALDH1A1 (0.41) | ALDH1A1CYP3A4CYP2C19CYP2C9POLB | |
| SCHEMBL9904879 | 0.82 | ALDH1A1 (0.41) | ALDH1A1CYP3A4CYP2C19CYP2C9POLB | |
| SCHEMBL15236865 | 0.82 | ALDH1A1 (0.36) | ALDH1A1CYP3A4CYP2C19CYP2C9POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260069559-A1 | COMBINATIONS OF RXFP1 MODULATORS AND SGLT2 INHIBITORS | ASTRAZENECA AB (SE) | 2026-03-12 | — | — | US | disclosed |
| US-20260069558-A1 | RXFP1 MODULATORS FOR TREATING RESISTANT HYPERTENSION OR HEART FAILURE WITH PULMONARY HYPERTENSION | ASTRAZENECA AB (SE) | 2026-03-12 | — | — | US | disclosed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| WO-2025097104-A1 | THIENYL COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PGI DRUG DISCOVERY LLC (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-4536207-A1 | COMBINATIONS OF RXFP1 MODULATORS AND SGLT2 INHIBITORS | Astrazeneca AB (SE) | 2025-04-16 | — | — | EP | disclosed |
| EP-4536206-A1 | RXFP1 MODULATORS FOR TREATING RESISTANT HYPERTENSION OR HEART FAILURE WITH PULMONARY HYPERTENSION | Astrazeneca AB (SE) | 2025-04-16 | — | — | EP | disclosed |
| EP-4522154-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2025-01-16 | — | — | US | disclosed |
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2009117540-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009117540-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-24 | — | — | WO | disclosed |
| EP-0705817-A1 | New cannamide derivatives and their use as allergy inhibitors | TSUMURA & CO. (JP) | 1996-04-10 | — | — | EP | disclosed |
| US-5344845-A | Methyl 4(4-acetoxy-3-methoxycinnamanide and salts as an immunosuppressive drug for allergic reactions | TSUMURA & CO. (JP) | 1994-09-06 | — | — | US | disclosed |
| EP-0535250-A1 | NOVEL COMPOUNDS AND USE THEREOF AS MEDICINE | TSUMURA & CO. (JP) | 1993-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069559-A1 | COMBINATIONS OF RXFP1 MODULATORS AND SGLT2 INHIBITORS | RXFP1, RXFP2, RXFP4 | ALDH1A1 2557/4885CYP3A4 4079/4885CYP2C19 3925/4885 |
| US-20090275574-A1 | NOVEL COMPOUNDS-300 | CACNA1A, SCN10A, OPRM1 | ALDH1A1 2206/4885CYP3A4 598/4885CYP2C19 937/4885 |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | ALDH1A1 4238/4885CYP3A4 4781/4885CYP2C19 4876/4885 |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | ALDH1A1 4457/4885CYP3A4 3732/4885CYP2C19 3916/4885 |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | ALDH1A1 1304/4885CYP3A4 1604/4885CYP2C19 2245/4885 |
| US-20260069558-A1 | RXFP1 MODULATORS FOR TREATING RESISTANT HYPERTENSION OR HEART FAILURE WITH PULMONARY HYPERTENSION | RXFP1, RXFP3, RXFP2 | ALDH1A1 2913/4885CYP3A4 4753/4885CYP2C19 4572/4885 |
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | ALDH1A1 539/4885CYP3A4 319/4885CYP2C19 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.